-
1Academic Journal
Πηγή: II Международная научно-практическая конференция "Преобразование современного мира: проблемы и возможности". :16-19
Θεματικοί όροι: beta-blockers, статины, angina pectoris, lipid spectrum, бета-адреноблокаторы, стенокардия, ИБС, липидный спектр, ischemic heart disease, statins
-
2Academic Journal
Συγγραφείς: I. E. Bachmakov, A. N. Fedoseev, V. E. Denisova
Πηγή: Качественная клиническая практика, Vol 0, Iss 4, Pp 68-77 (2024)
Θεματικοί όροι: блокада альфа1-рецепторов, бета-адреноблокаторы, 3. Good health, RS1-441, сердечно-сосудистый риск, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, хроническая болезнь почек, симпатическая нервная система, Medical technology, терминальная стадия хронической болезни почек, кардиоселективность, R855-855.5
Σύνδεσμος πρόσβασης: https://doaj.org/article/1dcd4b9f0b8e454cbc0a9fe1250dfa8f
-
3Academic Journal
Συγγραφείς: V. N. Fedorov, V. P. Vdovichenko, M. K. Korsakov, V. V. Strakhov, A. A. Popova, A. I. Khokhlov, S. S. Suleymanov
Πηγή: Качественная клиническая практика, Vol 0, Iss 3, Pp 44-54 (2023)
Θεματικοί όροι: 0301 basic medicine, бета-адреноблокаторы, альфа-2 адреномиметики, ингибиторы карбоангидразы, 3. Good health, глаукома закрытоугольная, RS1-441, аналоги простагландинов, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, внутриглазное давление, Medical technology, R855-855.5, глаукома открытоугольная
Σύνδεσμος πρόσβασης: https://doaj.org/article/47206004a0874c06b29c77e6c0fc7d35
-
4Academic Journal
Συγγραφείς: E. K. Kulbachinskaya, L. S. Gordeev, V. V. Bereznitskaya, Е. К. Кульбачинская, Л. С. Гордеев, В. В. Березницкая
Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 70, № 1 (2025); 42-49 ; Российский вестник перинатологии и педиатрии; Том 70, № 1 (2025); 42-49 ; 2500-2228 ; 1027-4065
Θεματικοί όροι: бета-адреноблокаторы, catecholaminergic polymorphic ventricular tachycardia, bidirectional ventricular tachycardia, flecainide, sudden cardiac death, beta-blockers, катехоламинергическая полиморфная желудочковая тахикардия, двунаправленная желудочковая тахикардия, флекаинид, внезапная сердечная смерть
Περιγραφή αρχείου: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/2138/1565; Roston T.M., Yuchi Z., Kannankeril P.J., Hathaway J., Vinocur J.M., Etheridge S.P., et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: Findings from an international multicentre registry. Europace 2018; 20(3): 541–547. DOI:10.1093/europace/euw389; Josephs K., Patel K., Janson C.M., Montagna C., McDonald V.T. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. Mol Genet Genomic Med. 2017; 5(6): 788–794. DOI:10.1002/mgg3.323; Кульбачинская Е.К., Березницкая В.В. CASQ2: клинико-генетические особенности катехоламинергической полиморфной желудочковой тахикардии в трех семьях. Альманах клинической медицины 2023; 51(3): 192–199. DOI 10.18786/2072–0505–2023–51–022; Webster G., Aburawi E.H., Chaix M.A., Chandler S., Foo R., Monwarul Islam A.K.M., et al. Life-threatening arrhythmias with autosomal recessive TECRL variants. Europace 2021; 23(5): 781–788. DOI:10.1093/europace/euaa376; Wang G., Zhao N., Zhong S., Wang Y., Li J. Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis. Medicine 2019; 98(34): p e16961. DOI:10.1097/MD.0000000000016961; Galimberti E.S., Knollmann B.C. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 2011; 51(5): 760–768. DOI:10.1016/j.yjmcc.2011.07.002; Marx A., Lange B., Nalenz C., Hoffmann B., Rostock T., Konrad T. A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Reports 2019; 5(2): 74–77. DOI:10.1016/j.hrcr.2018.04.003; Li S., Lv T., Yang J., Li K., Yang Y., Zhang P. A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia. Clin Exp Pharmacol Physiol 2023; 50 (1): 39–49. DOI:10.1111/1440–1681.13722; Veith M., El-Battrawy I., Roterberg G., Raschwitz L., Lang S., Wolpert C., et al. Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Clin Med. 2020; 9(4): 123–131. DOI:10.3390/jcm9040903; Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A., et al. Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J, 2022. 43(40): p. 3997–4126. DOI:10.1161/CIR.0000000000000548; Duan H., Lu Y., Yan S., Qiao L., Hua Y., Li Y., et al. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. Medicine (Baltimore) 2018; 97(16): 63–68. DOI:10.1097/MD.0000000000010368; Friday K.P., Moak J.P., Fries M.H., Iqbal S.N. Catecholaminergic Ventricular Tachycardia, Pregnancy and Teenager: Are They Compatible? Pediatric Cardiology 2015; 36(7): 1542–1547. DOI:10.1007/s00246–015–1232–3; Hwang H.S., Hasdemir C., Laver D., Mehra D., Turhan K., Faggioni M., et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class i antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circulation: Arrhythmia and Electrophysiology 2011; 4(2): 128–135. DOI:10.1161/CIRCEP.110.959916; Lawrenz W., Krogmann O.N., Wieczorek M. Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene. Cardiol Young 2014; 24 (4): 741–744. DOI:10.1017/S1047951113001091; Kulbachinskaya E., Bereznitskaya V. Long-term clinical course of patients with catecholaminergic polymorphic ventricular tachycardia: A more than 10-year follow-up cohort study. Annals of Pediatric Cardiology 2024; 17 (3): 196–203. DOI:10.4103/apc.apc_101_24
-
5Academic Journal
Συγγραφείς: Caracaş, A., Guţu, I.A., Bacinschi, N.G., Bachinsky, N.
Πηγή: Sănătate Publică, Economie şi Management în Medicină 102 (5) 112-119
Θεματικοί όροι: диабетогенный эффект, diabet zaharat, diabetes mellitus, diabetogenic effect, beta-adrenoblockers, бета-адреноблокаторы, сахарныйдиабет, beta-adrenoblocante, antihypertensive, антигипертензивные средства, efect diabetogen, antihipertensive
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: https://ibn.idsi.md/vizualizare_articol/215782
-
6Academic Journal
Συγγραφείς: Stadnik, S.M.
Πηγή: INTERNATIONAL NEUROLOGICAL JOURNAL; № 1.87 (2017); 87-92
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; № 1.87 (2017); 87-92
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; № 1.87 (2017); 87-92Θεματικοί όροι: когнітивні розлади, фібриляція передсердь, превентивна терапія, бета-адреноблокатори, аміодарон, cognitive disorders, atrial fibrillation, preventive treatment, beta-blockers, amiodarone, когнитивные нарушения, фибрилляция предсердий, превентивная терапия, бета-адреноблокаторы, амиодарон, 3. Good health
Περιγραφή αρχείου: application/pdf
-
7Academic Journal
Συγγραφείς: Radchenko, G.D.
Πηγή: HYPERTENSION; № 2.52 (2017); 9-34
АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ; № 2.52 (2017); 9-34
АРТЕРІАЛЬНА ГІПЕРТЕНЗІЯ; № 2.52 (2017); 9-34Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, артериальная гипертензия, антигипертензивная терапия, бета-адреноблокаторы, карведилол, обзор, артеріальна гіпертензія, антигіпертензивна терапія, бета-адреноблокатори, огляд, arterial hypertension, antihypertensive therapy, beta-blockers, carvedilol, review, 3. Good health
Περιγραφή αρχείου: application/pdf
-
8Academic Journal
Πηγή: Кардиология в Беларуси. :200-210
Θεματικοί όροι: 03 medical and health sciences, beta-blockers, 0302 clinical medicine, антигипертензивная терапия, ренальная денервация, бета-адреноблокаторы, blood pressure, резистентная артериальная гипертензия, renal denervation, antihypertensive therapy, артериальное давление, 3. Good health, resistant arterial hypertension
-
9Academic Journal
Πηγή: Педиатрия. Восточная Европа. :107-118
Θεματικοί όροι: внезапная сердечная смерть, ECG, синдром удлиненного интервала QT, бета-адреноблокаторы, дети, кардиовертер-дефибриллятор, corrected QT interval, ЭКГ, sudden cardiac death, 3. Good health, canalopathy, 03 medical and health sciences, beta-blockers, 0302 clinical medicine, children, cardioverter-defibrillator, каналопатии, long QT syndrome, корригированный интервал QT
-
10Academic Journal
Συγγραφείς: R. E. Yakubtsevich, K. O. Kratkou
Πηγή: Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 20, Iss 1, Pp 13-20 (2022)
Θεματικοί όροι: эндотелиальная дисфункция, ангиотензин ii, ингибиторы рецепторов ангиотензин-превращающего фермента, бета-адреноблокаторы, сенситизаторы кальция, левосимендан, нитраты, ингибиторы фосфодиэстеразы iii типа, милринон, Medicine
Περιγραφή αρχείου: electronic resource
Relation: http://journal-grsmu.by/index.php/ojs/article/view/2751; https://doaj.org/toc/2221-8785; https://doaj.org/toc/2413-0109
Σύνδεσμος πρόσβασης: https://doaj.org/article/88e322a0bc4e486685ee7a798e1b8025
-
11Academic Journal
Συγγραφείς: POPESCU, Liuba, CARAUȘ, Alexandru, MOISEEVA, Anna, COTELEA, Ana
Πηγή: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 75 No. 1 (2023): Medical Sciences; 112-117 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 75 Nr. 1 (2023): Ştiinţe medicale; 112-117 ; Вестник Академии Наук Молдовы. Медицина; Том 75 № 1 (2023): Медицина; 112-117 ; 1857-0011 ; 10.52692/10.52692/1857-0011.2023.1-75
Θεματικοί όροι: бета-адреноблокаторы, атеросклероз, beta-adrenoblocante, boala arteriala aterosclerotică, beta-adrenoblockers, atherosclerosis
Περιγραφή αρχείου: application/pdf
Relation: https://bulmed.md/bulmed/article/view/3522/3525; https://bulmed.md/bulmed/article/view/3522
-
12Academic Journal
Συγγραφείς: Catcov, C., Chişlaru, S., Rakovskaia, T.
Πηγή: Sănătate Publică, Economie şi Management în Medicină 93-S (2) 241-245
Θεματικοί όροι: амиодарон, cardiac comorbidities, beta-adrenoblockers, бета-адреноблокаторы, amiodaronă, beta-adrenoblocante, сопутствующие заболевания сердца, comorbidități cardiace, antiarrhythmics, amiodarone, антиаритмические препараты, antiaritmice
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: https://ibn.idsi.md/vizualizare_articol/171872
-
13Academic Journal
Πηγή: University Therapeutic Journal, Vol 3, Iss 3 (2022)
Θεματικοί όροι: хроническая сердечная недостаточность, пожилой возраст, ингибиторы ангиотензин превращающего фермента (иАПФ), антагонисты рецепторов ангиотензина II (АРА), бета адреноблокаторы (БАБ), антагонисты минералокортикоидных рецепторов (АМКР), Medicine
Περιγραφή αρχείου: electronic resource
Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/3842; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920
Σύνδεσμος πρόσβασης: https://doaj.org/article/39903838ee9d456d9e7d658203a93385
-
14Academic Journal
Πηγή: University Therapeutic Journal, Vol 3, Iss 3 (2022)
Θεματικοί όροι: пожилой возраст, антагонисты минералокортикоидных рецепторов (АМКР), ингибиторы ангиотензин превращающего фермента (иАПФ), Medicine, антагонисты рецепторов ангиотензина II (АРА), бета адреноблокаторы (БАБ), хроническая сердечная недостаточность
Σύνδεσμος πρόσβασης: https://doaj.org/article/39903838ee9d456d9e7d658203a93385
-
15Academic Journal
Συγγραφείς: A. V. Kuroyedov, Z. M. Nagornova, Z. U. Tibieva, E. A. Krinitsyna, V. M. Sergeeva
Πηγή: Российский офтальмологический журнал, Vol 11, Iss 2, Pp 71-81 (2018)
Θεματικοί όροι: carbonic anhydrase inhibitors, beta blockers, аддитивная терапия, симпатомиметики, бета-адреноблокаторы, фиксированные комбинации, ингибиторы карбоангидразы, м-холиномиметики, fixed combinations, RE1-994, глаукома, 3. Good health, аналоги простагландинов, Ophthalmology, 03 medical and health sciences, glaucoma, additive therapy, combined therapy, 0302 clinical medicine, prostaglandin analogues, cholinomimetics, комбинированная терапия, sympathomimetics
-
16Academic Journal
Συγγραφείς: Mareev V.Y., Fomin I.V., Ageev F.T., Begrambekova Y.L., Vasyuk Y.A., Garganeeva A.A., Gendlin G.E., Glezer M.G., Gautier S.V., Dovzhenko T.V., Kobalava Z.D., Koziolova N.A., Koroteev A.V., Mareev Y.V., Ovchinnikov A.G., Perepech N.B., Tarlovskaya E.I., Chesnikova A.I., Shevchenko A.O., Arutyunov G.P., Belenkov Y.N., Galyavich A.S., Gilyarevsky S.R., Drapkina O.M., Duplyakov D.V., Lopatin Y.M., Sitnikova M.Y., Skibitsky V.V., Shlyakhto E.V.
Πηγή: Kardiologiia
Θεματικοί όροι: функциональный класс сердечной недостаточности, рекомендации, Cardiology, heart failure, functional class of heart failure, хроническая сердечная недостаточность, Russia, 03 medical and health sciences, 0302 clinical medicine, myocardium, физические тренировки, Humans, guidelines, mineralocorticoid receptor antagonists, 10. No inequality, Societies, Medical, Heart Failure, антагонисты минералокортикоидных рецепторов, диуретики, 4. Education, physical exercises, бета-адреноблокаторы, Acute decompensated heart failure, left ventricular ejection fraction, миокард, сердечная недостаточность, diuretics, chronic heart failure, ACE Inhibitors, beta-adrenergic blocker agents, фракция выброса левого желудочка, острая декомпенсация сердечной недостаточности, ингибиторы АПФ
-
17Academic Journal
Συγγραφείς: Shikhova, E. I., Шихова, Е. И.
Πηγή: Сборник статей
Θεματικοί όροι: INFANTILE HEMANGIOMA, BETA BLOCKERS, HEMANGIOMA TREATMENT, ИГ – ИНФАНТИЛЬНАЯ ГЕМАНГИОМА, БЕТА-АБ – БЕТА-АДРЕНОБЛОКАТОРЫ, ЖНВЛП – ЖИЗНЕННО НЕОБХОДИМЫЕ И ВАЖНЕЙШИЕ ЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ, ГДКЦ – ГОРОДСКОЙ ДЕТСКИЙ КАРДИОЛОГИЧЕСКИЙ ЦЕНТР, ХМЭКГ – ХОЛТЕРОВСКОЕ МОНИТОРИРОВАНИЕ ЭЛЕКТРОКАРДИОГРАММЫ, ВК – ВРАЧЕБНАЯ КОМИССИЯ
Περιγραφή αρχείου: application/pdf
Relation: Актуальные вопросы детской кардиологии и ревматологии: материалы Юбилейной научно-практической конференции Городского детского кардиоревматологического центра ГАУЗ СО «ДГКБ № 11» (29–30 октября 2021 года, в комбинированном формате, Екатеринбург, Россия) / под ред. С. А. Царьковой. – Екатеринбург : ИЗДАТЕЛЬСТВО АМБ, 2021. – 116 с.; http://elib.usma.ru/handle/usma/4779
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/4779
-
18Academic Journal
Συγγραφείς: A. Matveev V., E. Egorova A., E. Konyaeva I., A. Dormidor G., E. Bekirova Yu., А. Матвеев В., Е. Егорова А., Е. Коняева И., А. Дормидор Г., Э. Бекирова Ю.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 5 (2021); 779-784 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 5 (2021); 779-784 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: beta-blockers, adverse event, psoriasis, Raynaud's syndrome, vitiligo, бета-адреноблокаторы, нежелательные реакции, псориаз, синдром Рейно, витилиго
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2591/2236; Prichard BN, Gillam PM. Use of propranolol (Inderal) in treatment of hypertension. Br Med J. 1964;2(5411):725-27. DOI:10.1136/bmj.2.5411.725.; Ogrodowczyk M, Dettlaff K, Jelinska A. Beta-Blockers: Current State of Knowledge and Perspectives. Mini Rev Med Chem. 2016;16(1):40-54. DOI:10.2174/1389557515666151016125948.; Wiysonge CS, Opie LH. β-Blockers as initial therapy for hypertension. JAMA. 2013;310(17):1851-2. DOI:10.1001/jama.2013.277510.; do Vale GT, Ceron CS, Gonzaga NA, et al. Three Generations of β-blockers: History, Class Differences and Clinical Applicability. Curr Hypertens Rev. 2019;15(1):22-31. DOI:10.2174/1573402114666180918102735.; Laurent S. Antihypertensive drugs. Pharmacol Res. 2017;124:116-25. DOI:10.1016/j.phrs.2017.07.026.; Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev. 2016;3(3):CD007451. DOI:10.1002/14651858.CD007451.pub2.; Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017;11(1):54-65. DOI:10.1016/j.jash.2016.11.007.; Kendall MJ, Beeley L. Beta-adrenoceptor blocking drugs: adverse reactions and drug interactions. Pharmacol Ther. 1983;21(3):351-69. DOI:10.1016/0163-7258(83)90060-8.; Мартимьянова Л.А., Макиенко Н.В., Усань Н.Ю. Блокаторы бета-адренорецепторов в терапевтической клинике. Вестник ХНУ им. В.Н. Каразина. Серия Медицина. 2008;16(831):95-103.; Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134(5):749-60. DOI:10.1016/s0002-9394(02)01699-9.; Frishman WH. Beta-adrenergic receptor blockers. Adverse effects and drug interactions. Hypertension. 1988;11(3):II21-II29. DOI:10.1161/01.hyp.11.3_pt_2.ii21.; O'Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 2006;5(5):426-32.; Yilmaz MB, Turhan H, Akin Y, et al. Beta-blocker-induced psoriasis: a rare side effect--a case report. Angiology. 2002;53(6):737-9. DOI:10.1177/000331970205300617.; Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl). 2017;7:87-94. DOI:10.2147/PTT.S126727.; Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000;1(3):159-65. DOI:10.2165/00128071-200001030-00003.; Dika E, Varotti C, Bardazzi F, et al. Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol. 2006;25(1):1-11. DOI:10.1080/15569520500536568.; Stanford CW, Kollipara R, Melookaran AM, et al. Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate. Cutis. 2014;94(3):153-5.; Sehgal VN, Dogra S, Srivastava G, et al. Psoriasiform dermatoses. Indian J Dermatol Venereol Leprol. 2008;74(2):94-9. DOI:10.4103/0378-6323.39688.; Glass LR, Nguyen M, Winn BJ, et al. Timolol drops causing reversible psoriatic fingernail changes. JAMA Ophthalmol. 2013;131(9):1134. DOI:10.1001/jamaophthalmol.2013.1579.; Heng MC, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption. Clinical and pathogenetic aspects. Int J Dermatol. 1988 ;27(9):619-27. DOI:10.1111/j.1365-4362.1988.tb02419.x.; Armstrong AW. Psoriasis Provoked or Exacerbated by Medications: Identifying Culprit Drugs. JAMA Dermatol. 2014;150(9):963. DOI:10.1001/jamadermatol.2014.1019.; Wu S, Han J, Li WQ, et al. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014;150(9):957-63. DOI:10.1001/jamadermatol.2013.9957.; Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol—the role of an immunological mechanism. Arch Dermatol Res. 1991;283(7):472-3. DOI:10.1007/BF00371785.; Levin A, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014;70(3):555-61. DOI:10.1016/j.jaad.2013.10.043.; McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009;10(3):314-24. DOI:10.1038/ni.1698.; Awad VM, Sakhamuru S, Kambampati S, et al. Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level. Cureus. 2020;12(7):e8964. DOI:10.7759/cureus.8964.; Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatol (Oxford). 2005;44(5):587-96. DOI:10.1093/rheumatology/keh552.; Roustit M, Khouri C, Blaise S, et al. Pharmacology of Raynaud's phenomenon. (in French). [Pharmacologie du phenomene de Raunald]. Therapie. 2014;69(2):115-28. DOI:10.2515/therapie/2013068.; Suter LG, Murabito JM, Felson DT, et al. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum. 2005;52(4):1259-63. DOI:10.1002/art.20988.; De Angelis R, Salaffi F, Grassi W. Raynaud's phenomenon: prevalence in an Italian population sample. Clin Rheumatol. 2006;25(4):506-10. DOI:10.1007/s10067-005-0077-1.; Khouri C, Jouve T, Blaise S, Carpentier P, et al. Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis. Br J Clin Pharmacol. 2016;82(2):549-60. DOI:10.1111/bcp.12980.; Heintzen MP, Strauer BE. Peripheral vascular effects of beta‐blockers. Eur Heart J. 1994;15(C):2-7. DOI:10.1093/eurheartj/15.suppl_c.2.; VandenBurg MJ, Evans SJW, Cooper WD, et al. Is the feeling of cold extremities experienced by hypertensive patients due to their disease or their treatment? Eur J Clin Pharmacol. 1984;27(1):47-9.; Rolfes L, de Swart-Ruijter I, van Hunsel F. Labetalol for hypertension during pregnancy and nipple pain. Eur J Obstet Gynecol Reprod Biol. 2014;182:254-5. DOI:10.1016/j.ejogrb.2014.09.041.; Avila-Vega J, Urrea-Mendoza E, Lee C. Raynaud's phenomenon of the nipple as a side-effect of labetalol: Case report and literature review. Case Rep Womens Health. 2019;23:e00135. DOI:10.1016/j.crwh.2019.e00135.; Mcguinness N, Cording V. Raynaud's phenomenon of the nipple associated with labetalol use. J Hum Lact. 2012;29(1):17-9. DOI:10.1177/0890334412467509.; Schallreuter KU. Beta-adrenergic blocking drugs may exacerbate vitiligo. Br J Dermatol. 1995;132:168-9. DOI:10.1111/j.1365-2133.1995.tb08660.x.; Wu CS, Yu HS, Chang HR, et al. Cutaneous blood flow and adrenoceptor response increase in segmental-type vitiligo lesions. J Dermatol Sci. 2000;23(1):53-62. DOI:10.1016/S0923-1811(99)00090-0.; Tatu AL, Elisei AM, Chioncel V, et al. Immunologic adverse reactions of β-blockers and the skin. Exp Ther Med. 2019;18(2):955-9. DOI:10.3892/etm.2019.7504.; Choi ME, Yoo H, Lee HR, et al. Carvedilol, an Adrenergic Blocker, Suppresses Melanin Synthesis by Inhibiting the cAMP/CREB Signaling Pathway in Human Melanocytes and Ex Vivo Human Skin Culture. Int J Mol Sci. 2020;21(22):8796. DOI:10.3390/ijms21228796.; Lang DM. Anaphylactoid and Anaphylactic Reactions. Hazards of beta-blockers. Drug-Safety. 1995;12(5):299-304. DOI:10.2165/00002018-199512050-00002.; Goddet NS, Descatha A, Liberge O, et al. Paradoxical reaction to epinephrine induced by beta-blockers in an anaphylactic shock induced by penicillin. Eur J Emerg Med. 2006;13(6):358-60. DOI:10.1097/01.mej.0000217993.09364.35.; Toogood JH. Beta-blocker therapy and the risk of anaphylaxis. CMAJ. 1987;137(7):587-8.; Jacobs RL, Rake GW, Fournier DC, et al. Potentiated anaphylaxis in patients with drug-induced betaadrenergic blockade. J Allergy Clin Immunol. 1981;68(2):125-7. DOI:10.1016/0091-6749(81)90170-6.; Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371-6. DOI:10.1016/j.jaci.2004.04.029.; Lee S, Hess EP, Nestler DM, et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol. 2013;131(4):1103-8. DOI:10.1016/j.jaci.2013.01.011.; Coop CA, Schapira RS, Freeman TM. Are ACE Inhibitors and Beta-blockers Dangerous in Patients at Risk for Anaphylaxis? J Allergy Clin Immunol Pract. 2017;5(5):1207-11. DOI:10.1016/j.jaip.2017.04.033.; Francuzik W, Dölle-Bierke S, Knop M, et al. Refractory Anaphylaxis: Data From the European Anaphylaxis Registry. Front Immunol. 2019;10:2482. DOI:10.3389/fimmu.2019.02482.; Francuzik W, Ruёff F, Bauer A, et al. Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry. J Allergy Clin Immunol. 2021;147(2):653-62. DOI:10.1016/j.jaci.2020.06.008.; Pathak A, Mrabeti S. beta-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? Vasc Health Risk Manag. 2021;17:337-348. DOI:10.2147/VHRM.S285907.; https://www.rpcardio.com/jour/article/view/2591
-
19Academic Journal
Συγγραφείς: V. Larina N., M. Leonova V., В. Ларина Н., М. Леонова В.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 5 (2021); 752-760 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 5 (2021); 752-760 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: genetic polymorphism, beta1-adrenergic receptors, beta-blockers, arterial hypertension, heart failure, atrial fibrillation, генетический полиморфизм, бета1-адренорецепторы, бета-адреноблокаторы, артериальная гипертония, сердечная недостаточность, фибрилляция предсердий
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2588/2233; Hollenberg NK. The role of beta-blockers as a cornerstone of cardiovascular therapy. Am J Hypertens. 2005;18(12 Pt 2):165S-168S. DOI:10.1016/j.amjhyper.2005.09.010.; Nonen S, Azuma J, Fujio Y. Pharmacogenomics of adrenergic receptors; from hypertension to heart failure. Open Hypertens J. 2010;3:14-20. DOI:10.2174/1876526201003010014.; Moore JD, Mason DA, Green SA, et al. Racial differences in the frequencies of cardiac β1-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mut 1999;14(3):271. DOI:10.1002/(SICI)1098-1004(1999)14:33.0.CO;2-Q.; Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem. 1999;274(18):12670-4. DOI:10.1074/jbc.274.18.12670.; Bruck H, Leineweber K, Temme T, et al. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. JACC. 2005;46(11):2111-5. DOI:10.1016/j.jacc.2005.08.041.; Levin MC, Marullo S, Muntaner O, et al. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem. 2002;277(34):30429-35. DOI:10.1074/jbc.M200681200.; O'Shaughnessy KM, Fu B, Dickerson C, et al. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond). 2000;99(3):233-8. DOI:10.1042/cs0990233.; Sofowora GG, Dishy V, Muszkat M, et al. A common β1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin Pharmacol Ther. 2003;73(4):366-71. DOI:10.1016/s0009-9236(02)17734-4.; Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003;74(4):372-9. DOI:10.1067/S0009-9236(03)00224-8.; Johnson JA, Zineh I, Puckett BJ, et al. Beta1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003;74(1):44-52. DOI:10.1016/S0009-9236(03)00068-7.; Liu J, Liu ZQ, Yu BN, et al. Вeta1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006;80(1):23-32. DOI:10.1016/j.clpt.2006.03.004.; Sehrt D, Meineke I, Tzvetkov M, et al. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics. 2011;12(6):783-95. DOI:10.2217/pgs.11.20.; Si D, Wang J, Xu Y, et al. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol. J Cardiovasc Pharmacol. 2014;64(4):306-9. DOI:10.1097/FJC.0000000000000119.; Suonsyrjä T, Donner K, Hannila-Handelberg T, et al. Common genetic variation of beta1- and beta2- adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics. 2010;20(5):342-5. DOI:10.1097/FPC.0b013e328338e1b8.; Pacanowski MA, Gong Y, Cooper-DeHoff RM, et al., on behalf of For the INVEST Investigators. β- adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008; 84(6):715-21. DOI:10.1038/clpt.2008.139.; Magvanjav O, McDonough CW, Gong Y, et al., NINDS SiGN (Stroke Genetics Network). Pharmacogenetic associations of β1-adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke. 2017;48(5):1337-43. DOI:10.1161/STROKEAHA.116.015936.; Borjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J. 2000;21(22):1853-8. DOI:10.1053/euhj.1999.; Magnusson Y, Levin MC, Eggertsen R, et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. 2005;78(3):221-31. DOI:10.1016/j.clpt.2005.06.004.; White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta1-adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003;5(4):463- 8. DOI:10.1016/s1388-9842(03)00044-8.; Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103(30):11288-93. DOI:10.1073/pnas.0509937103.; Fiuzat M, Neely ML, Starr AZ, et al. Association between adrenergic receptor genotypes and betablocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail. 2013;15(3):258-66. DOI:10.1093/eurjhf/hfs175.; Parikh KS, Fiuzat M, Davis G, et al. Dose-Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018;11(8):e002210. DOI:10.1161/CIRCGEN.117.002210.; Kang S, Hong X, Ruan CW, et al. Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure. J Transl Med. 2015;13:44. DOI:10.1186/s12967-015-0402-7.; Terra SG, Hamilton KK, Pauly DF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics. 2005;15(4):227-34. DOI:10.1097/01213011-200504000-00006.; Terra SG, Pauly DF, Lee CR, et al. Вeta-аdrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther. 2005;77(3):127-37. DOI:10.1016/j.clpt.2004.10.006.; Mialet PJ, Rathz DA, Petrashevskaya NN, et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9(10):1300-5. DOI:10.1038/nm930.; Molenaar P, Chen L, Semmler AB, et al. Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through 'affinity states' and polymorphism. Clin Exp Pharmacol Physiol. 2007;34(10):1020-8. DOI:10.1111/j.1440-1681.2007.04730.x.; Chen L, Meyers D, Javorsky G, et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics. 2007;17(11):941-9. DOI:10.1097/FPC.0b013e3282ef7354.; Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the longterm effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther. 2010;24(1): 9-60. DOI:10.1007/s10557-010-6220-5.; de Groote P, Helbecque N, Lamblin N, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics. 2005;15(3):137-42. DOI:10.1097/01213011-200503000-00001.; Liu WN, Fu KL, Gao HY, et al. β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis. PLoS One. 2012;7(7):e37659. DOI:10.1371/journal.pone.0037659.; Muthumala A, Drenos F, Elliott PM, Humphries SE. Role of β adrenergic receptor polymorphisms in heart failure: Systematic review and meta-analysis. Eur J Heart Fail. 2008;10(1):3-13. DOI:10.1016/j.ejheart.2007.11.008.; Parvez B, Chopra N, Rowan S, et al. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol. 2012;59(1):49-56. DOI:10.1016/j.jacc.2011.08.061.; https://www.rpcardio.com/jour/article/view/2588
-
20Academic Journal
Συγγραφείς: A. Proshlyakov Yu., P. Chomakhidze Sh., N. Novikova A., А. Прошляков Ю., П. Чомахидзе Ш., Н. Новикова А.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 3 (2021); 492-497 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 3 (2021); 492-497 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: beta-blockers, prolonged QT interval, propranolol, metoprolol, atenolol, nadolol, bisoprolol, бета-адреноблокаторы, удлиненный интервал QT, пропранолол, метопролол, атенолол, надолол, бисопролол
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2514/2194; Rautaharju PM, Surawicz B, Gettes LS. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram Part IV: The ST Segment, T and U Waves, and the QT Interval A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology, the American College of Cardiology Foundation, and the Heart Rhythm Society Circulation. 2009,1 19:241-50. DOI:10.1016/j.jacc.2008.12.014.; Pickham D, Hasanien A.A. ECG Challenges: Measurement and Rate Correction of the QT Interval. AACN Advanced Critical Care 2013,24(1):90-6. DOI:10.1097/NCI.0b013e318274ba3e.; Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003,289(4):2120-7. DOI:10.1001/jama.289.16.2120.; Дощицин В.Л. Клинический анализ электрокардиограммы. М: Медицина, 1 982.; Kuszakowski MS. Cardiac arrhythmias. St. Petersburg: IKF Foliant, 1998 (In Russ.) [Кушаковский М.С. Аритмии сердца. СПб.: ИКФ Фолиант, 1998].; Макаров Л.М., Чупрова С.Н., Киселева И.И. Сравнение способов измерения интервала QT и их клиническое значение. Кардиология. 2004,(5):71-3.; Kannankeril P, Roden DM, Darbar D. Drug-Induced Long QT Syndrome. Pharmacol Rev. 2010,62(4): 760-81. DOI:10.1124/pr.110.003723.; Chiang CE, Roden DM. The long-QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol. 2000,36(1):1-12. DOI:10.1016/s0735-1097(00)00716-6.; Doschitsin VL, Segal ES, Sedov VV. ECG QT interval prolongation: classification, clinical significance. Kardiologiia. 1981,10:22-8 (In Russ.) [Дощицин В.Л., Сигал Е.С., Седов В.В. Удлинение интервала QT ЭКГ: классификация, клиническое значение. Кардиология. 1981,10:22-8].; Schwartz PJ, Crotti L, Insolia R. Long-QTsyndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012,5(4):868-77. DOI:10.1161/CIRCEP.111.962019.; Refsgaard L, Holst AG, Sadjadieh G, et al. High prevalence of genetic variants previously associated with LQT syndrome in new exome data. Eur J Hum Genet. 2012,20(8):905-8. DOI:10.1038/ejhg.2012.23.; Antzelevitch C, Oliva A. Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes. J Intern Med. 2006,259(1):48-58. DOI:10.1111/j.1365-2796.2005.01587.x.; Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol. 2000,36(1):1-12. DOI:10.1016/s0735-1097(00)00716-6.; Nakano Y Shimizu W. Genetics of long-QT syndrome. J Hum Genet 2016,61 (1 ):51-5. DOI:10.1038/jhg.2015.74.; Modell SM, Lehmann MH. The long-QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med. 2006,8(3):143-55.; Moss AJ, Robinson J. Clinical features of the idiopathic long QT syndrome. Circulation. 1 992,85(1 Suppl):I140-4.; Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991,84(3):1 136-44. DOI:10.1161/01.cir.84.3.1136.; Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015,36(41):2793-867. DOI:10.1093/eurheartj/ehv316.; Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J. 1 985,1 09(2):399-411. DOI:10.1016/0002-8703(85)90626-x.; Vincent GM. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med. 1998,49:263-74. DOI:10.1146/annurev.med.49.1.263.; Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol. 2018,72(14):e91-e220. DOI:10.1016/j.jacc.2017.10.054.; Priori SG, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013,1 5(10):1 389-406. DOI:10.1093/europace/eut272.; Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and response to therapy in long-QT syndrome type 2. Heart Rhythm. 2010,7(12):1797-805. DOI:10.1016/j.hrthm.2010.09.011.; Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001 ,103(1 ):89-95. DOI:10.1161/01.cir.103.1.89.; Goldenberg I, Thottathil P, Lopes CM, et al. Trigger-specific ion-channel mechanisms, risk factors, and response to therapy in type 1 long QT syndrome. Heart Rhythm/ 2012 ,9( 1) :49-56. DOI:10.1016/j.hrthm.2011.08.020.; Лопатин Ю.М. Диуретики и развитие гиперкалиемии у больных артериальной гипертонией: одинакова ли безопасность оригинальных и генерических препаратов. Атмосфера. Кардиология. 2004,(3):12-5.; Schwartz PJ, Moss AJ, Vincent GM. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993,88(2):782-4. DOI:10.1161/01.cir.88.2.782.; Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000,101(6):616-23. DOI:10.1161/01.cir.101.6.616.; Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004,292(1 1 ):1 341-4. DOI:10.1001/jama.292.11.1341.; Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. Eur Heart J. 2004,25(1 6):1 405-1 1. DOI:10.1016/j.ehj.2004.06.016.; Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012,60(20):2092-9. DOI:10.1016/j.jacc.2012.07.046.; Chatrath R, Bell CM, Ackerman MJ. Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome. Pediatric Cardiology. 2004,25(5):459-65. DOI:10.1007/s00246-003-0567-3.; Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation. 2009,119(2):215-21. DOI:10.1161/CIRCULATIONAHA.108.772533.; Ackerman MJ. Genotype-phenotype relationships in congenital long QT syndrome. J Electrocardiol. 2005,38(4 Suppl):64-8. DOI:10.1016/j.jelectrocard.2005.06.018.; Ali RH, Zareba W, Moss AJ, et al. Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol. 2000,85(4):457-61. DOI:10.1016/s0002-9149(99)90772-5.; McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990,46(2):163-97. DOI:10.1016/0163-7258(90)90092-g.; Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs: an update. Drug Saf. 1993,9(4):272-9. DOI:10.2165/00002018-199309040-00005.; Calvillo L, Spazzolini C, Vullo E, et al. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients. Heart Rhythm. 2014,1 1(1):1 26-32. DOI:10.1016/j.hrthm.2013.10.029.; Wilde AA, Moss AJ, Kaufman ES, et al. Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study Circulation. 2016,1 34(1 2):872-82. DOI:10.1161/CIRCULATIONAHA.116.021823.; Besana A, Wang DW, George AL Jr, Schwartz PJ. Nadolol block of Nav1.5 does not explain its efficacy in the long-QT syndrome. J Cardiovasc Pharmacol. 2012,59(3):249-53. DOI:10.1097/FJC.0b013e31823d2fd1.; Abu-Zeitone A, Peterson DR, Polonsky B, et al. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol. 2014,64(1 3):1352-8. DOI:10.1016/j.jacc.2014.05.068.; Goldenberg I, Bradley J, Moss AJ, et al. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol. 2010,21(8):893-901. DOI:10.1111/j.1540-8167.2010.01737.x.; Ahn J, Kim HJ, Choi JI, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis. PLoS ONE. 2017,12(10):e0185680. DOI:10.1371/journal.pone.0185680.; Steinberg C, Padfield GJ, Al-Sabeq B, et al. Experience with bisoprolol in long-QT 1 and long-QT2 syndrome. J Interv Card Electrophysiol. 2016,47(2):1 63-70. DOI:10.1007/s10840016-0161-2.; Mazzanti A, Maragna R, Vacanti G, et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. J Am Coll Cardiol. 2018,71(1 5):1663-71. DOI:10.1016/j.jacc.2018.01.078.; Wang DW, Mistry AM, Kahlig KM, et al. Propranolol blocks cardiac and neuronal voltage-gated sodium channels. Front Pharmacol. 2010,1:144. DOI:10.3389/fphar.2010.00144.; Fazio G, Vernuccio F, Lo Re G, et al. Role of bisoprolol in patients with long QT syndrome. Ann Noninvasive Electrocardiol. 2013,18(5):467-70. DOI:10.1111/anec.12047.; Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Heart Rhythm. 2020,17(9):1 425-33. DOI:10.1016/j.hrthm.2020.05.014.; Koponen M, Marjamaa A, Hiippala A, et al. Follow-Up of 316 Molecularly Defined Pediatric Long-QT Syndrome Patients. Circ Arrhythm Electrophysiol. 2015,8(4):815-23. DOI:10.1161/CIR-CEP.114.002654.; Itoh T, Kikuchi K, Odagawa Y et al. Correlation of genetic etiology with response to beta-adrenergic blockade among symptomatic patients with familial long-QT syndrome. Journal of Human Genetics. 2001,46(1):38-40. DOI:10.1007/s100380170123.; Mizusawa Y Horie M, Wilde AA. Genetic and clinical advances in congenital long QT syndrome. Circulation journal: official journal of the Japanese Circulation Society 2014,78(1 2):2827-33. DOI:10.1253/circj.cj-14-0905.; Goldenberg I, Zareba W, Moss AJ. Long QT Syndrome. Curr Probl Cardiol. 2008,33(1 1):629-94. DOI:10.1016/j.cpcardiol.2008.07.002.; Amin AS, Asghari-Roodsari A, Tan HL. Cardiac sodium channelopathies. Pflugers Arch. 2010,460(2):223-37. DOI:10.1007/s00424-009-0761-0.; Ishibashi K, Aiba T, Kamiya C, et al. Arrhythmia risk and p-blocker therapy in pregnant women with long QT syndrome. Heart. 2017,103(1 7):1374-9. DOI:10.1136/heartjnl-2016-310617.; Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy Eur Heart J. 2018,39(34):3165-241. DOI:10.1093/eurheartj/ehy340.; Seth R, Moss A.J, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007,49(10):1 092-8. DOI:10.1016/j.jacc.2006.09.054.; Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and cate-cholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017,14(1):e41-e44. DOI:10.1016/j.hrthm.2016.09.012.; https://www.rpcardio.com/jour/article/view/2514